Pituitary Adenoma Case Review & Coordination

• Pituitary-protocol MRI with and without contrast, preferably with thin sellar cuts.
• DICOM image files, not only the written radiology report.
• Radiology report describing tumor size, microadenoma vs macroadenoma, optic chiasm relationship, cavernous sinus involvement, sphenoid/sellar anatomy and any suprasellar extension.
• Prior MRI or CT studies for comparison, especially if growth or recurrence is suspected.
• If surgery is being considered, any available ENT or sinus history can also be relevant for transnasal/transsphenoidal planning.

• Prolactin, IGF-1, cortisol/ACTH-related testing where relevant, TSH and free T4, LH/FSH, estradiol or testosterone, and other pituitary axis results already performed.
• Dynamic endocrine tests, such as dexamethasone suppression, oral glucose suppression or stimulation tests, if they were used locally.
• Electrolytes, especially sodium, if there are symptoms suggesting adrenal insufficiency, diabetes insipidus, SIADH or perioperative risk.
• Symptoms suggesting hormone excess or deficiency, including menstrual/fertility changes, sexual dysfunction, galactorrhea, acromegaly features, Cushingoid features, fatigue, low blood pressure or unexplained weight changes.
• Current hormone replacement or endocrine medications, including dopamine agonists, somatostatin analogues, steroid replacement, thyroid replacement, sex hormone therapy or desmopressin.

• Formal visual field testing if the adenoma abuts or compresses the optic nerves or chiasm, or if vision symptoms are present.
• Visual acuity and ophthalmology notes, if available.
• Description of peripheral vision loss, double vision, eye movement problems, optic nerve findings or progressive visual symptoms.
• Baseline results are especially important when comparing observation, surgery and follow-up pathways.

• Previous neurosurgery reports, including transsphenoidal surgery details if already performed.
• Histology/pathology report, immunohistochemistry and any tumor classification data.
• Radiation or radiosurgery reports, if previously treated.
• Medication response history, especially for prolactinoma or acromegaly-related adenomas.
• Postoperative endocrine course, including adrenal function, diabetes insipidus, sodium problems, hormone replacement and follow-up MRI results.

Some pituitary lesions are found incidentally or appear non-functioning. The key pathway question is whether the adenoma is small and stable, large enough to affect the optic chiasm, growing over time, or already causing hypopituitarism. Coordination should therefore focus on pituitary MRI, visual field status, baseline endocrine testing and a clear follow-up plan.

Observation may be appropriate in selected cases, while surgery is more likely to be discussed when there is visual pathway compression, neurological compromise, clinically relevant growth or other features requiring active treatment.

For prolactin-secreting adenomas, the pathway often differs from other pituitary tumors because medication with dopamine agonists is commonly central to management. A good review file should include prolactin levels, medication history, response and tolerance, pregnancy/fertility context where relevant, MRI findings and visual status.

Surgery may still be discussed in selected cases, such as medication intolerance, resistance, diagnostic uncertainty, compressive symptoms, apoplexy or patient-specific factors. Healwise’s role is to coordinate the specialist review, not to determine suitability for any treatment.

When growth hormone excess is suspected or confirmed, the pathway usually requires endocrine confirmation, IGF-1 and GH-related testing, evaluation of comorbidities, pituitary MRI and specialist discussion. Treatment pathways may include transsphenoidal surgery, medical therapy, radiation or combined management depending on tumor anatomy and biochemical control.

Coordination is especially important when prior surgery or medication has not controlled the disease, because the review may need to compare repeat surgery, medication escalation, radiosurgery/radiotherapy and long-term endocrine follow-up.

ACTH-secreting pituitary adenomas require careful endocrine confirmation before treatment planning. The case file may need cortisol testing, ACTH results, dynamic testing, pituitary MRI, information about comorbidities and prior endocrine evaluation. Because borderline or incomplete testing can lead to confusion, document preparation is particularly important.

When Cushing disease is confirmed, transsphenoidal pituitary surgery is commonly considered as a first-line pathway by specialist teams, while persistent or recurrent disease may require additional surgery, medication, radiation or other individualized strategies.

If the adenoma abuts or compresses the optic chiasm, formal visual field testing and high-quality MRI become central to pathway planning. The review may focus on whether there is current visual deficit, progressive loss, cavernous sinus extension, surgical accessibility and perioperative endocrine risk.

For surgical candidates, the pathway often includes pituitary neurosurgery, endocrinology, anesthesia, possible ENT input, preoperative hormone replacement planning and clear postoperative monitoring for adrenal insufficiency, diabetes insipidus and sodium disturbances.

Sudden severe headache with visual loss, double vision, reduced consciousness or acute endocrine instability may indicate pituitary apoplexy or another emergency. This situation should be assessed locally and urgently. Once the patient is medically stabilized, Healwise can help organize records, imaging, endocrine data and communication with a pituitary specialist team for further planning.

After prior surgery, medication or radiation, review often depends on operative notes, pathology, serial MRI, hormone trends, visual outcomes and current symptoms. The next pathway may involve observation, repeat surgery, medication, radiosurgery/radiotherapy or long-term endocrine management. Structured documentation helps the specialist team understand what has already been tried and what risk remains.